Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Saved in:
| Title: | Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. |
|---|---|
| Authors: | Penny HL; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States., Hainline K; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States., Theoharis N; Labcorp, Translational Biomarker Solutions, Greenfield, IN, United States., Wu B; Department of Biologics, Amgen, Thousand Oaks, CA, United States., Brandl C; Department of Translational Safety & Bioanalytical Sciences, Amgen Research (Munich) GmbH, Munich, Germany., Webhofer C; Department of Process Development, Amgen Research (Munich) GmbH, Munich, Germany., McComb M; Department of Clinical Pharmacology, Modeling & Simulation, Amgen, Thousand Oaks, CA, United States., Wittemer-Rump S; Bayer AG, Research and Development Oncology (RED Onc), Pharmaceuticals, Berlin, Germany., Koca G; Bayer AG, Research and Development Oncology (RED Onc), Pharmaceuticals, Berlin, Germany., Stienen S; Department of Early Development (Oncology), Amgen Research (Munich) GmbH, Munich, Germany., Bargou RC; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, Wurzburg, Germany., Hummel HD; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, Wurzburg, Germany., Loidl W; Department of Urology, Ordensklinikum Linz GmbH, Linz, Austria., Grüllich C; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Medical Center, Heidelberg, Germany., Eggert T; Department of Early Development (Oncology), Amgen, Thousand Oaks, CA, United States., Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Mytych DT; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2023 Oct 23; Vol. 14, pp. 1261070. Date of Electronic Publication: 2023 Oct 23 (Print Publication: 2023). |
| Publication Type: | Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37942314 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Penny+HL%22">Penny HL</searchLink>; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States.<br /><searchLink fieldCode="AU" term="%22Hainline+K%22">Hainline K</searchLink>; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States.<br /><searchLink fieldCode="AU" term="%22Theoharis+N%22">Theoharis N</searchLink>; Labcorp, Translational Biomarker Solutions, Greenfield, IN, United States.<br /><searchLink fieldCode="AU" term="%22Wu+B%22">Wu B</searchLink>; Department of Biologics, Amgen, Thousand Oaks, CA, United States.<br /><searchLink fieldCode="AU" term="%22Brandl+C%22">Brandl C</searchLink>; Department of Translational Safety & Bioanalytical Sciences, Amgen Research (Munich) GmbH, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Webhofer+C%22">Webhofer C</searchLink>; Department of Process Development, Amgen Research (Munich) GmbH, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22McComb+M%22">McComb M</searchLink>; Department of Clinical Pharmacology, Modeling & Simulation, Amgen, Thousand Oaks, CA, United States.<br /><searchLink fieldCode="AU" term="%22Wittemer-Rump+S%22">Wittemer-Rump S</searchLink>; Bayer AG, Research and Development Oncology (RED Onc), Pharmaceuticals, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Koca+G%22">Koca G</searchLink>; Bayer AG, Research and Development Oncology (RED Onc), Pharmaceuticals, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Stienen+S%22">Stienen S</searchLink>; Department of Early Development (Oncology), Amgen Research (Munich) GmbH, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Bargou+RC%22">Bargou RC</searchLink>; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, Wurzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Hummel+HD%22">Hummel HD</searchLink>; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, Wurzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Loidl+W%22">Loidl W</searchLink>; Department of Urology, Ordensklinikum Linz GmbH, Linz, Austria.<br /><searchLink fieldCode="AU" term="%22Grüllich+C%22">Grüllich C</searchLink>; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Medical Center, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Eggert+T%22">Eggert T</searchLink>; Department of Early Development (Oncology), Amgen, Thousand Oaks, CA, United States.<br /><searchLink fieldCode="AU" term="%22Tran+B%22">Tran B</searchLink>; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Mytych+DT%22">Mytych DT</searchLink>; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2023 Oct 23; Vol. 14, pp. 1261070. <i>Date of Electronic Publication: </i>2023 Oct 23 (<i>Print Publication: </i>2023). – Name: TypePub Label: Publication Type Group: TypPub Data: Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37942314 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fimmu.2023.1261070 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1261070 Titles: – TitleFull: Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Penny HL – PersonEntity: Name: NameFull: Hainline K – PersonEntity: Name: NameFull: Theoharis N – PersonEntity: Name: NameFull: Wu B – PersonEntity: Name: NameFull: Brandl C – PersonEntity: Name: NameFull: Webhofer C – PersonEntity: Name: NameFull: McComb M – PersonEntity: Name: NameFull: Wittemer-Rump S – PersonEntity: Name: NameFull: Koca G – PersonEntity: Name: NameFull: Stienen S – PersonEntity: Name: NameFull: Bargou RC – PersonEntity: Name: NameFull: Hummel HD – PersonEntity: Name: NameFull: Loidl W – PersonEntity: Name: NameFull: Grüllich C – PersonEntity: Name: NameFull: Eggert T – PersonEntity: Name: NameFull: Tran B – PersonEntity: Name: NameFull: Mytych DT IsPartOfRelationships: – BibEntity: Dates: – D: 23 M: 10 Text: 2023 Oct 23 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1664-3224 Numbering: – Type: volume Value: 14 Titles: – TitleFull: Frontiers in immunology Type: main |
| ResultId | 1 |
